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Objective. We are developing a hybrid arterial bypass graft of compliant poly(carbonate–urea)urethane (MyoLinke),
endothelial and smooth muscle cells (SMCs). To enhance adhesion of SMCs we assessed various attachment factors and the
effect of pre-conditioning on cell retention.
Methods. MyoLink segments were coated with either RGD, superfibronectin, fibronectin, fibronectin-like engineered
polymer protein (FEPP), FEPP plus or type 1 collagen overnight. 111Indium-radiolabelled SMCs were placed onto MyoLink
segments for 48 h before being aspirated, then lavaged off. All grafts, aspirates and lavages were counted in a gamma counter.
SMC viability on the MyoLink segments was also assessed for viability using the Alamar blue redox assay. Separately,
MyoLink grafts lined with radiolabelled SMCs were divided into a pre-conditioned group, exposed to subarterial pulsatile
flow whilst another group were held in static culture. After 1-week, grafts were exposed to arterial pulsatile flow whilst
radioactivity was assessed using a gamma camera.
Results. Only FEPP plus significantly enhanced SMC attachment: mean of 32 ^ 6% cell attachment compared to
21 ^ 5% for uncoated control. Cell viability was enhanced by all attachment factors except fibronectin. Pre-conditioning
was shown to significantly enhance the retention of SMCs onto the MyoLink once exposed to pulsatile arterial flow: the final
attachment was 57 ^ 7% for the static and 76 ^ 7% for the pre-conditioned group.
Conclusions. FEPP plus enhances SMC attachment to MyoLink. We believe this is because of its repeating sequences of
RGD and its positive charge. Pre-conditioning enhances the retention of SMCs to MyoLink once exposed to pulsatile arterial
flow.
Key Words: Cell adhesion; Cell retention; Compliance; FEPP plus; Hybrid graft; Polyurethanes; RGD; Shear stress; Smooth
muscle cell; Tissue engineering.
Introduction
Obstructive atherosclerotic vascular disease in the
form of cardiovascular and cerebrovascular disease is
the largest cause of mortality and morbidity in the
USA and Europe.1 When angioplasty or stenting of the
occluded vessels is not possible or unsuccessful then
the surgical treatment for coronary artery and lower
limb ischaemia involve the use of bypass grafts. For
the majority of interventions this involves the use of
the long saphenous vein or even the cephalic and
basilic veins harvested from the arm or leg of the
patient. However, in about a third of patients this
source proves inadequate or unsuitable.2 Therefore
surgeons have turned to prosthetic materials like
polyethylene terephthalate (Dacron) and expanded
polytetrafluoroethylene (PTFE). However, these pros-
thetic materials prove to be inferior to venous
conduits, especially when the vessel diameter is under
5 mm, with lower patency and higher infection rates.3–5
There are two important causes of the high failure
rates in current prosthetic grafts, namely mechanical
failings such as compliance mismatch between native
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artery and prosthetic graft6 – 8 and biological failings
including absence of antithrombogenic properties and
a living, responsive tissue adaptive to changes in the
local environment.9
In an attempt to improve this situation, research has
focused on three strategies: (a) newer types of
prosthetic material; (b) making the existing prosthetic
materials more natural by lining the lumen of the graft
with endothelial cells (seeding) and (c) growing
completely new vascular conduits from autogenous
material using tissue-engineering techniques.
In this study, we describe the development of a
hybrid graft using compliant poly(carbonate-urea)ur-
ethane (MyoLinke) as a simple scaffold onto which
SMCs and extra-cellular matrix (ECM) develop.
The MyoLink graft has a honeycomb structure that
allows it to maintain compliance similar to that of
human artery10 and pulsatile flow in vivo through a
mechanism of wall compression that accommodates
increases in volume without the need for external
dilation. This is an advance on previous polyurethane
based grafts which exhibited a compliance mismatch
caused by perivascular ingrowth.11 MyoLink has been
shown to have superior ability to attach endothelial
cells (EC), which can be further improved by pre-lining
the graft with attachment factors like collagen and
fibronectin.10 – 13 The graft has undergone in vitro
degradation tests and has been implanted in a dog
model for 36 months, demonstrating very high biost-
ability.14–16 This graft is already in use as an A–V fistula
for haemodialysis access and is undergoing a phase I
clinical trial as a peripheral vascular bypass graft.14
Essentially all peptides promoting cell adhesion are
derived from sequences found in ECM molecules. Of
these fibronectin (FN) and vitronectin are the primary
serum glyoproteins promoting cell adhesion, and FN
has been the most studied.17 FN is a glycoprotein
(,250,000 Da) with a modular structure. It contains
domains for binding fibrin, heparin, gelatin, collagen,
EC, and has cysteine and arginine-glycine-aspartate
(RGD) residues. Critically this RGD amino acid
sequence18 in the 10th type III repeat of FN serves as
a primary cell attachment cue.19 RGD is the most
studied and effective peptide for cell adhesion on
synthetic surfaces, based upon its widespread distri-
bution within organisms, its ability to address more
than one cell adhesion receptor and its biological
impact upon cell anchoring, behaviour and survival.
Furthermore cell adhesive RGD sites have been found
in other ECM proteins like vitronectin, collagen,
fibrinogen, von Willebrand factor, laminin, membrane
proteins and even viral and bacterial proteins.20
Integrins are the main cell receptors for ECM
proteins like FN, laminin, collagens, vitronectin and
so are the main mediators of cell–cell and cell–ECM
adhesion.19 Integrin–ECM interactions are highly
promiscuous: there is evidence that upon binding
different integrins, the same ECM protein (e.g. FN) can
mediate different functions and one integrin can bind
multiple ligands. Integrins are heterodimers of two
noncovalently associated glycoproteins, a and b: there
are 18a and 8b subunits combining to form at least 24
heterodimers.21 About half have been shown to bind to
ECM molecules in an RGD-dependent manner.20
Although FN significantly improves EC retention,
fibronectin is susceptible to hydrolysis,17 so we
decided to compare FN to variations of FN and to
compounds containing only the RGD peptide
sequence as it was hypothesised that increasing the
number of RGD motifs in engineered constructs
would result in significant improvements in cell
adhesion. Attachment factors tested were RGD itself;
superfibronectin (SFN) where a fragment from the first
type-III repeat of fibronectin is bound to fibronectin to
produce disulphide cross-linking thus resulting in
multimers of the RGD motif of high molecular mass;22
fibronectin like engineered polymer protein (FEPP) a
segmented copolymer consisting of amino acid
sequence blocks modelled on the crystalline segments
of silk fibroin and the RGD domain of human
fibronectin23 and fibronectin like engineered polymer
protein plus (FEPP þ ) where multiple copies of the
RGD sequence are engineered within a positively
charged copolymer.24
Furthermore studies have shown that EC attach-
ment can be enhanced by lining synthetic grafts with
SMC first.25,26
Another factor shown to positively influence the
development of tissue-engineered grafts is called ‘pre-
conditioning’. Here the vascular construct is exposed,
in vitro, to pulsatile flow and pressure. This has been
shown to enhance cell proliferation, tissue formation
and mechanical properties.27 Our laboratory has
previously shown that pre-conditioning with physio-
logical shear stress using a flow circuit28 – 30 we have
developed can significantly enhance EC retention,
viability and morphology.
Our laboratory is on the process of developing a
hybrid graft consisting of a compliant scaffold (Myo-
Link), SMCs and ECs sourced from the same patient.
The first stage is to produce a SMC layer mimicking
the arterial media, so that the eventual hybrid graft
could be vasoreactive. This would have the added
benefit of enhancing EC adherence compared to pure
EC seeding of grafts (i.e. without SMCs). In order to
have a viable SMC layer it must be able to resist the
forces of arterial shear stress. Hence we investi-
gated what impact pre-conditioning would have on
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cell retention at arterial pressures and flows. There-
fore, the aim of this study was to determine whether
attachment factors, and specifically those with mul-
tiple repeats of the RGD sequence, could enhance the
adhesion of SMCs to the MyoLink and to examine the
effect on cell retention of our pre-conditioning
technique.
Methods and Materials
Material chemistry and manufacture of poly(carbonate-
urea)urethane ‘MyoLink’
The chemistry and manufacture of this graft have been
published.31 Briefly, it is made of poly(carbonate-
urea)urethane extruded via low temperature cast
coagulation. All grafts were 4 mm in internal diameter.
Cell extraction and culture
Human umbilical vein and arterial smooth muscle
cells (SMC) were extracted using a novel enzymatic
extraction process developed in-house.32 Briefly: seg-
ments of umbilical artery and vein were cleaned of
adventitia and sequentially treated with various
concentrations of collagenase and elastase. SMCs
were serially cultured in SMC tissue culture medium.
This medium consisted of DMEM (Dulbecco’s modi-
fied Eagle’s medium) with HEPES modification, 10%
FBS (foetal bovine serum), 2 mM L-glutamine,
2.5 mcg/ml amphotericin B, 100 units/ml penicillin
and 100 mcg/ml streptomycin. The SMCs were
stained with a-actin to confirm their SMC status.
Cell radiolabelling
The cells were used when confluent on the sixth
passage. After trypsinization and resuspension in
SMC medium, a cell count was obtained and cells
were radiolabelled according to a protocol we have
developed33 with 1.8 MBq 111In-oxine (Amersham
International, Amersham, Bucks, UK) per 106 cells
(incubated at 37 8C, 15 min). The cells were sub-
sequently diluted in SMC medium to the concen-
tration necessary to achieve a seeding density of
2.25 £ 105 cells/cm2.
Lining MyoLink with attachment factors and radiolabelled
SMCs
Lengths of MyoLink were filled with either: RGD
(Arg-Gly-Asp) at 633 mcg/ml, superfibronectin at
42 mcg/ml, fibronectin at 118 mcg/ml, FEPP
118 mcg/ml, FEPP plus 133 mcg/ml or type 1 collagen
at 1 mg/ml (all from Sigma-Aldrich). A control batch
consisted of native graft without a coating. The grafts
were then left for 24 h to allow the scaffolds to be
soaked with the various attachment factors. At the end
of the 24 h period, the excess of the attachment factors
were poured off.
The next day the grafts were cut along their length
and then into 1–2 cm long pieces. These MyoLink
segments were then placed in 2 ml syringes with the
plungers holding them in position and the MyoLink
lumen facing upwards. The syringes were filled with
0.7 ml of SMC solution at 2.25 £ 106 cells/ml.
After 48 h in an incubator, the solution was
aspirated off and the MyoLink inner lumens were
lavaged with sterile phosphate buffered saline (PBS).
The aspirate and washings were collected in separate
tubes. Then the radioactivity of all specimens was
determined using a gamma counter.
From the counts, the percentage radioactivity of the
MyoLink was calculated as below:
%Radioactivity on MyoLink
¼ MyoLink £ 100
MyoLink þ Aspirate þ Lavages þ Syringe
The radioactivity reflected the number of SMCs.
Cell viability
Viability of seeded cells were assessed using Alamar
bluee (Serotec Ltd, Kidlington, Oxford, UK) assay, as
per our previous protocol.34
Briefly, the MyoLink segments were inserted into
wells of a 24-well plate and filled with 1 ml of 10%
Alamar bluee (Alamar blue diluted 1:10 in SMC
medium) and spectroscopic analysis was performed at
4 h by removing a 50.0 ml aliquot into a 96-well plate
and absorbance read spectroscopically at wavelengths
of 570 and 630 nm (Labsystems Multiscan MS visible
spectrophotometer). Segments were subjected to scan-
ning electron microscopy (SEM) for the presence and
morphological appearance of seeded cells.
Effect of shear force on cell retention by pulsatile arterial
flow
We modified the validated flow system of Giudicean-
drea et al.33 to simulate in vitro the pulsatility and flow
waveform including reverse flow, pressures, and
degree of oxygenation and pH of physiological
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femoral artery circulation in vivo. We used this model
to accurately determine SMC adhesiveness and reten-
tion on grafts exposed to physiological shear stress.
To investigate the impact of pre-conditioning, eight
grafts were lined with radiolabelled SMCs as per the
above method. Four of the grafts were left in static
culture and four were pre-conditioned in the above
flow circuit.12 In both experiments, the grafts were
incubated at 37 8C and 5% CO2. After a week the grafts
were put into a pulsatile flow circuit and dynamic
scintigraphy images were acquired using a gamma
camera.12,33,35
Radioactivity from the 111In-oxine-labelled SMCs
was measured using a gamma camera scanner linked
to an image processing system. The section of the
circuit containing the vascular grafts was positioned
over the gamma camera and imaged throughout the
perfusion period. An on-line workstation recorded all
images within 64 £ 64 matrices. The initial six images
were each acquired over 5 min, with 22 subsequent
images acquired over a 15 min span and used to
generate time-activity curves corrected for back-
ground, spontaneous indium leakage, and isotope
decay (half-life of 111In ¼ 68 h). Cell attachment (CA)
with respect to time was calculated from the equation
below, where ðtÞn is time in minutes, ðtÞ0 is immedi-
ately before initiation of flow, and CPMG and CPMB
are the counts per minute over the graft and back-
ground computed from analysis of dynamic scinti-
graphy images. Grafts were perfused for 8 h.
CA ¼ CellsðtÞn
CellsðtÞ0 £ 100
¼ CPMGðtÞn 2 CPMBðtÞn
CPMGðtÞn £ 100
Data analysis and statistical methods
Experiments were repeated six times. Data are
presented with mean ^ standard deviation (SD). For
the cell attachment and viability data, the different
groups are compared using 1-way ANOVA test using
Bonferroni’s multiple comparison test. For the time-
activity retention data, at each time point the two
groups were compared using an unpaired t-test.
Results
Assessment of cell attachment
The impact of the various attachment factors on cell
attachment are summarised in Fig. 1. FEPP þ was
significantly better than the native MyoLink ðp , 0:01Þ
in terms of attachment of the SMCs, with a mean of
32 ^ 6% cell attachment compared to 21 ^ 5% for the
native graft as calculated by the radiolabelling
method.
Cell viability
Alamar blue at 4 h showed that every attachment
factor except FN resulted in significantly higher ðp ,
0:01Þ metabolic activity compared to native (Fig. 2).
Pre-conditioning
Before exposure of the cells to the shear force of
pulsatile blood flow, there was 8% lower cell count as
determined by radioactivity levels on the vascular
grafts in the preconditioning group compared to the
static group, but this was not statistically significant
(303 ^ 22 vs. 280 ^ 35, p ¼ 0:106).
Upon commencement of the pulsatile flow circuit,
the percentage of original radioactivity was signifi-
cantly lower in the static grafts (81 ^ 3 vs. 93 ^ 2 for
pre-conditioned grafts) after only 5 min ðp , 0:0001Þ:
When assessing absolute values, however, the differ-
ence only became significant after 60 min ðp ¼ 0:02Þ
because of the higher initial values in the static group
(Fig. 3). At the end of the study period of 8 h, the
values had plateaued, with the final % values being a
mean of 57 ^ 7 for the static group and 76 ^ 7 for the
pre-conditioned group.
Discussion
Cell–cell and cell–ECM interactions through integrins
and other cell surface adhesion receptors are import-
ant for SMC adhesion, migration, proliferation, con-
traction, differentiation and apoptosis.36 Integrins are
important in SMC adhesion to ECM proteins like
collagen.37 Vitronectin and fibronectin are ECM
proteins that mediate attachment of SMCs to both
natural scaffolds like collagen and synthetic scaffolds
like polyesters of lactic and glycolic acid.38 RGD is a
tripeptide sequence (arginine-glycine-aspartate)
found in extracellular matrix proteins like fibronectin.
It is the binding motif for cell surface integrin receptors
and has been investigated extensively.39 – 43 Our
laboratory has shown that RGD when covalently
bonded to MyoLink and particularly when this was
in association with heparin, significantly enhances the
retention and viability of seeded ECs.44
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Fig. 1. SMC attachment with various attachment factors. Mean ^ standard deviation. FN, fibronectin; SFN, superfibronectin;
FEPP, fibronectin-like engineered polymer protein; FEPP þ , fibronectin-like engineered polymer protein plus; RGD, Arg-
Gly-Asp.
Fig. 2. Impact of various attachment factors on cell viability. Mean ^ standard deviation. SFN, superfibronectin; FEPP,
fibronectin-like engineered polymer protein; FEPP þ , fibronectin-like engineered polymer protein plus; FN, fibronectin;
RGD, Arg-Gly-Asp.
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We report a method for assessing attachment of
SMCs to MyoLink using different attachment factors.
By radiolabelling the SMCs, we have shown that the
only type of attachment factor that significantly
improves the attachment of SMCs compared to the
native MyoLink graft is FEPP Plus.
Alamar blue at 4 h showed that there were more
viable cells attached using any of the attachment
factors, except FN, compared to native ðp , 0:01Þ:
Our belief is that the reason for the superiority of
the FEPP plus is that it has a positive charge, which has
been shown to attract the negatively-charged surface
of cells45,46 and it contains repeating sequences of
RGD47 which would enhance the binding of SMCs,
principally through integrin receptors, to the MyoLink
surface coated with RGD peptides. Further exper-
iments are needed to determine if there is a time-
dependent factor to the attachment.
Although coating the graft with attachment factors
rather than bonding is a well-known methodology, it is
true that this is not as reliable as bonding attachment
factors to the graft. However, bonding is usually done
for small peptides not larger repeats of peptide
sequences. Furthermore, in our experience SMCs
tend to grow into the pores of the honeycomb of
poly(carbonate-urea)urethane. This compares to ECs,
which sit on the surface. We have previously shown
that bonding small peptide sequences with spacer arm
technology improves EC attachment to the surface.44
However, due to the amorphous crystalline nature of
polyurethanes such bonding occurs post extrusion as
an additional step and as such makes this procedure
commercially less favourable as it is expensive and
time consuming. If such a step is not required for SMC,
which would not be confined to the graft surface, this
makes the cost effectiveness of tissue-engineered
hybrid constructs of EC and SMC commercially
more acceptable. In addition, bonding is not a cost-
effective technology for screening through a host of
different attachment factors. Mechanical stress orien-
tates SMCs and the ECM both in vitro or in vivo.48 – 59
The exposure of tissue-engineered vessels to the
mechanical stimulation of pulsatile flow results in
increased mechanical strength of the constructs as
measured by parameters like burst pressure.29,30,60 – 63
This is critical if implanted vessels are to avoid
aneurysmal dilation and ultimately rupture once
exposed to long-term arterial blood pressures. The
optimum conditions of the pre-conditioning are still to
be defined but some propose that the ideal for tissue-
engineered vessels may actually be fetal conditions64
with low pulsatile pressure but high pulse rates.
Furthermore exposure to shear stress has been shown
to enhance endothelial cell attachment, retention and
differentiation as well as being a critical factor in their
biological regulatory function.65 – 69 SMC proliferation
also is enhanced by shear stress.70 Although for this
study shear stress was not measured, this variable is
currently under investigation in our laboratory.
We have shown in this study that the use of pre-
conditioning significantly enhances the retention of
SMCs on MyoLink. This is not just a proliferative effect
because rather than cell counts or metabolic assays we
measured SMC numbers by radioactivity after having
radiolabelled the SMCs at the start of the experiment.
Therefore any proliferation could not increase the total
amount of radioactivity and any decrease in radioac-
tivity measured by the gamma camera could only be
because of the detachment of radiolabelled SMCs.
Indeed SEM confirms the superiority of pre-con-
ditioned over static grafts (Fig. 4) with much greater
cell coverage.
In conclusion, the goal of achieving a compliant
hybrid graft has been partially realised by the
development of the MyoLink scaffold which matches
arterial compliance within the human blood pressure
range.13 This work has shown that pre-conditioning
with pulsatile flow together with the use of FEPP plus
as a peptide coating for the graft gives excellent SMC
adhesion when exposed to shear stress. This work has
only been taken to 8 h in the in vitro setting and further
studies are focussed on long-term assessment in vitro
and in vivo, of SMC attachment and the development
of a neomedia.
Fig. 3. Effect of pre-conditioning on SMC retention to
MyoLink each value plotted is mean ^ standard deviation.
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